Galapagos reports encouraging initial results in clinical trial on reuma

April 14, 2015 News BioVox

Galapagos NV announced that the selective JAK1 inhibitor filgotinib improved the symptoms of active rheumatoid arthritis and met key efficacy endpoints after 12 weeks of treatment. This Phase 2B study achieved its primary endpoint with a statistically significant improvement versus the placebo. These first results in the ongoing 24 week study are consistent with the efficacy/safety profile of filgotinib observed in the prior 4-week clinical studies.

DARWIN 1 is an ongoing, 24 week, double-blind, placebo-controlled evaluation of filgotinib, with as once- and twice-daily administration (QD and BID dosing) at 3 daily dose levels. Results were reported for 594 patients with moderate to severe rheumatoid arthritis who showed an inadequate response to methotrexate and who remained on their background therapy of methotrexate. These patients received filgotinib or placebo and were evaluated up to 12 weeks, the time of the primary endpoint of the study. Galapagos expects to report the full 24 week results for DARWIN 1 around the middle of the year.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts


* indicates required

Intuit Mailchimp